BlueCross BlueShield of Tennessee Medical Policy Manual

Elosulfase Alfa (Vimizim®)

NDC CODE(S)

68135-0100-XX VIMIZIM 5 MG/5ML SOLN (BIOMARIN PHARMACEUTICALS

DESCRIPTION

Elosulfase alfa is a purified human enzyme produced by recombinant DNA technology.  It is used for enzyme replacement therapy for individuals with mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome). Mucopolysaccharidoses are a group of lysosomal storage disorders caused by the deficiency of specific enzymes required for the catabolism of glycosaminoglycans (GAG).  The enzyme deficient or absent in MPS IVA is N-acetylgalactosamine-6-sufatase leading to accumulation of the GAG substrates keratan sulfate (KS) and chondroitin-6-sulfate (C6S) throughout the body, eventually leading to widespread cellular, tissue and organ dysfunction.

POLICY

MEDICAL APPROPRIATENESS

INITIAL APPROVAL CRITERIA

Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome)

RENEWAL CRITERIA

DOSAGE/ADMINISTRATION

INDICATION

DOSE

Mucopolysaccharidosis IVA

2 mg/kg administered once every week as an intravenous (IV) infusion

LENGTH OF AUTHORIZATION

Coverage will be for 12 months and may be renewed.

DOSAGE LIMITS

Max Units (per dose and over time) [HCPCS Unit]:

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the ember's health plan must be reviewed.  If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.

ADDITIONAL INFORMATION 

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

SOURCES

1.     Vimizim [package insert]. Novato, CA; Biomarin Pharmaceutical Inc.; December 2019. Accessed January 2021.

2.     Regier DS, Oetgen M, Tanpaiboon P. Mucopolysaccharidosis Type IVA. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. 2013 Jul 11 [updated 2014 Mar 13].

3.     Hendriksz CJ, Berger KI, Giugliani R, et al. International Guidelines for the Management and Treatment of Morquio A Syndrome. Am J Med Genet A. 2015 Jan; 167(1): 11–25. Published online 2014 Oct 24. doi: 10.1002/ajmg.a.36833

4.     Regier DS, Oetgen M, Tanpaiboon P. Mucopolysaccharidosis Type IVA. 2013 Jul 11[Updated 2016 Mar 24]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK148668/

5.     Schweighardt B, Tompkins T, Lau K, et al. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. Clin Ther. 2015 May 1;37(5):1012-1021.e6. doi:10.1016/j.clinthera.2014.11.005. Epub 2014 Dec 6.

6.     Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014 Nov;37(6):979-90. doi: 10.1007/s10545-014-9715-6. Epub 2014 May 9.

7.     Lexi-Comp Online. (2020, March). AHFS DI. Elosulfase alfa. Retrieved February 1, 2021 from Lexi-Comp Online with AHFS.

8.     MICROMEDEX Healthcare Series. Drugdex Evaluations. (2020, January). Elosulfase alfa. Retrieved February 1, 2021 from MICROMEDEX Healthcare Series.

ORIGINAL EFFECTIVE DATE: 3/5/2014

MOST RECENT REVIEW DATE:    6/30/2021

ID_MRx

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information